Vivos Inc. filings document formal disclosures for a radiotherapeutic company developing RadioGel® for human applications and IsoPet® for veterinary use. The company’s 8-K reports record material definitive agreements, executive appointments, compensatory arrangements, and governance changes tied to its operating structure.
Regulatory filings also frame RDGL’s public-company disclosures around capital structure, shareholder voting matters, clinical and regulatory updates, and operating and financial results. These records provide the formal context for the company’s radionuclide therapy programs, manufacturing and development activities, and corporate governance matters.
Vivos Inc. (RDGL) director and 10% owner Carlton M. Cadwell disposed of 385,302 Series C Convertible Preferred shares to the issuer on October 7, 2026, in exchange for 385,302 Series D Convertible Preferred shares. He also acquired 250,000 additional Series D shares for $250,000; his reported direct Series D holdings after the transactions were 635,302 shares. Both preferred series are convertible at any time at the holder's election and do not expire. No Rule 10b5-1 plan is reported.
Vivos Inc. entered into a stock purchase and exchange agreement with Carl Cadwell, a member of its Board of Directors, on October 7, 2026. Cadwell agreed to purchase 250,000 Series D Convertible Preferred Stock shares for a purchase price of $250,000 and exchange 385,302 Series C shares for 385,302 Series D shares; the share exchange was consummated that day.
After the transaction, Vivos reported 635,302 Series D shares outstanding, with a conversion price of $.08 per share, and no Series C shares outstanding. On October 8, 2026, Vivos filed a Certificate of Elimination for Series C, effective that date; the board had approved the filing. The Series D shares issued under the agreement were described as exempt from Securities Act registration under Section 4(a)(2) and/or Rule 506(b) of Regulation D.
On September 28, 2026, VIVOS INC. designated 1.0 million of its 10.0 million authorized preferred shares as Series D Convertible Preferred Stock. Each Series D share has a $1.00 stated value and a $1.00 liquidation preference, ranks senior to Common Stock and equity securities ranking junior to it, and may be converted at the holder’s election into common shares equal to the stated value divided by $0.08, subject to adjustment under the designation.
Series D holders vote with Common Stock holders, with the equivalent of 50 votes for each common share issuable upon conversion. Conversion rights are limited if a holder’s beneficial ownership would exceed 4.99% immediately after conversion; the limit may be 9.99% after 61 days’ prior written notice to VIVOS.
Vivos Inc. (RDGL) CEO Michael K. Korenko purchased 200,000 common shares directly on September 30, 2026, at $0.498 per share. His direct holdings following the purchase were 11,635,090 shares. No Rule 10b5-1 plan is reported.
VIVOS INC (RDGL) President Brad Allan Weeks reported an open-market purchase of 25,550 shares of common stock on September 16, 2026 at a weighted average price of $0.0482 per share, with individual trade prices ranging from $0.048 to $0.0489. Following this transaction, he directly holds 1,547,204 shares of VIVOS INC common stock. No Rule 10b5-1 trading plan is reported for this purchase.
Vivos Inc. (RDGL) reported limited commercial activity and continuing losses for the six months ended June 30, 2026. Revenue was $72,468, primarily from IsoPet® product and related items, but cost of goods sold exceeded revenue, resulting in a gross loss. Operating expenses of $1.19 million produced an operating loss of $1.20 million, and after a $847,628 loss on share and warrant exchanges, the net loss reached $2,015,034.
Cash increased to $2,336,022, driven by $2,203,800 raised via Regulation A+ equity offerings and associated warrants, while total liabilities remained low at $123,955. The company has an accumulated deficit of $90.4 million and discloses that current cash is insufficient for its plans, estimating a need for about $3.0 million per year and $9.0 million over the next 36 months to fund operations and clinical development.
Management states there is substantial doubt about the ability to continue as a going concern absent additional capital. Strategically, Vivos highlights progress in its Precision Radionuclide Therapy™ platform, including FDA Breakthrough Device status, approval of an Early Feasibility IDE in July 2026 for a first-in-human study at Mayo Clinic, expansion of its IsoPet® animal-therapy network, and the consolidation of Vivos Scientific India LLP as a variable interest entity to support international clinical and manufacturing activities.
VIVOS INC President Brad Allan Weeks purchased 50,000 shares of Common Stock on 2026-08-10 at $0.0548 per share in an open market or private transaction. Following this purchase, he directly holds 1,521,654 shares of VIVOS INC Common Stock.
VIVOS INC CEO and President Michael K. Korenko purchased 150,000 shares of Common Stock on 2026-08-10 in a transaction classified as a purchase in an open market or private transaction. The shares were acquired at a price of $0.0531 per share, bringing his directly held stake to 11,435,090 shares after the transaction.
VIVOS INC President Brad Allan Weeks reported open-market purchases of company common stock. He bought 60,000 shares on July 21, 2026 and 32,000 shares on July 22, 2026, each at $0.05 per share, for a total of 92,000 shares acquired directly.
VIVOS INC President Brad Allan Weeks reported multiple acquisitions of Common Stock. He made open-market purchases totaling 60,000 shares on July 9–10, 2026 at $0.0800 per share and received stock grants totaling 247,270 shares in March and June 2026. Following these transactions, he directly owns 1,379,654 shares.